Korea Arlico Pharm KRX:260660KOSDAQ
알리코제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked5since Sep 11
In Q2 2026, Korea Arlico Pharm reported revenue of ₩46.9bn, down 6.8% year on year, and an operating loss of ₩4.6bn. Korea Arlico Pharm (알리코제약) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Insider buying Swung to loss Screener
Korea Arlico Pharm quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩46.9bn | -6.8% | −₩4.6bn margin −9.8% | −₩694m |
| Q1 2026 | ₩48.3bn | -4.1% | −₩1.8bn margin −3.6% | −₩621m |
| Q4 2025 derived | ₩48.3bn | -7.7% | −₩1.7bn margin −3.5% | −₩983m |
| Q3 2025 | ₩102bn | +109.9% | ₩1.7bn margin 1.6% | −₩21m |
| Q2 2025 | ₩50.3bn | +11.9% | ₩1.7bn margin 3.3% | ₩533m |
| Q1 2025 | ₩50.4bn | +13.6% | ₩1.0bn margin 2.0% | ₩399m |
| Q4 2024 derived | ₩52.3bn | +17.7% | −₩642m margin −1.2% | −₩1.7bn |
| Q3 2024 | ₩48.8bn | +8.3% | ₩1.3bn margin 2.6% | ₩1.1bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Korea Arlico Pharm top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Korea Arlico Pharm news Korean headlines
-
알리코제약, 지치 유래 PDRN 화장품 출시
1 more on this story · 1 outlets
- 알리코제약, 지치 유래 PDRN 크림 출시...약국시장 외형 확대팜뉴스 · Oct 13 07:30
-
알리코제약, 김대훈 대표 선임…이항구 회장과 각자대표 체제
1 more on this story · 1 outlets
- 알리코제약, 김대훈 대표 신규 선임…오너·전문경영인 각자대표 체제메디팜스투데이 · Sep 11 15:21